CA2434831C - Drogues a base de polypeptide - Google Patents

Drogues a base de polypeptide Download PDF

Info

Publication number
CA2434831C
CA2434831C CA2434831A CA2434831A CA2434831C CA 2434831 C CA2434831 C CA 2434831C CA 2434831 A CA2434831 A CA 2434831A CA 2434831 A CA2434831 A CA 2434831A CA 2434831 C CA2434831 C CA 2434831C
Authority
CA
Canada
Prior art keywords
peptide
species
pharmaceutical agent
composition
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2434831A
Other languages
English (en)
Other versions
CA2434831A1 (fr
Inventor
Robert H. Zimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmuPharma AG
Original Assignee
ImmuPharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmuPharma AG filed Critical ImmuPharma AG
Priority claimed from PCT/IB2002/000133 external-priority patent/WO2002056916A2/fr
Publication of CA2434831A1 publication Critical patent/CA2434831A1/fr
Application granted granted Critical
Publication of CA2434831C publication Critical patent/CA2434831C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux agents et de nouvelles compostions pharmaceutiques ainsi que de nouvelles méthodes qui améliorent l'absorption de substances médicamenteuses à base de polypeptides qui, normalement, présentent une absorbabilité faible ou inexistante si elles sont administrées par voie orale. Cette invention concerne également de nouvelles compositions et de nouvelles méthodes qui améliorent significativement la biodisponibilité et l'efficacité pharmacologique de substances médicamenteuses à base de polypeptides, qu'elles soient administrées par voie orale ou par voie parentérale.
CA2434831A 2001-01-17 2002-01-17 Drogues a base de polypeptide Expired - Lifetime CA2434831C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US26233701P 2001-01-17 2001-01-17
US60/262,337 2001-01-17
US28788601P 2001-05-01 2001-05-01
US25787201P 2001-05-01 2001-05-01
US60/287,886 2001-05-01
US60/257,872 2001-05-01
US33263601P 2001-11-06 2001-11-06
US60/332,636 2001-11-06
PCT/IB2002/000133 WO2002056916A2 (fr) 2001-01-17 2002-01-17 Compositions et methodes assurant une activite pharmacologique accrue au moyen de l'administration par voie orale et parenterale de compositions renfermant des substances medicamenteuses a base de polypeptides et d'autres ingredients actifs presentant une faible absorption

Publications (2)

Publication Number Publication Date
CA2434831A1 CA2434831A1 (fr) 2002-07-25
CA2434831C true CA2434831C (fr) 2012-03-06

Family

ID=27500604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2434831A Expired - Lifetime CA2434831C (fr) 2001-01-17 2002-01-17 Drogues a base de polypeptide

Country Status (4)

Country Link
JP (2) JP5057628B2 (fr)
CN (2) CN1545422B (fr)
AU (1) AU2002228260B2 (fr)
CA (1) CA2434831C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232716A (zh) * 2009-05-08 2019-01-18 上海泰飞尔生化技术有限公司 多肽和多肽相关化合物的高穿透力前药组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396606A (en) * 1979-11-05 1983-08-02 Addiction Research Foundation Novel polypeptide analgesics
CA1340588C (fr) * 1988-06-13 1999-06-08 Balraj Krishan Handa Derive d'aminoacides
EP1586584A1 (fr) * 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agrégation de peptides beta-amyloides, comprenant des D-aminoacides
US6174993B1 (en) * 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases

Also Published As

Publication number Publication date
CN101979093A (zh) 2011-02-23
AU2002228260B2 (en) 2007-02-08
JP2009235082A (ja) 2009-10-15
CN1545422B (zh) 2010-09-22
CN101979093B (zh) 2013-04-24
CA2434831A1 (fr) 2002-07-25
JP2005505492A (ja) 2005-02-24
JP5057628B2 (ja) 2012-10-24
CN1545422A (zh) 2004-11-10

Similar Documents

Publication Publication Date Title
JP4878732B2 (ja) 規制物質の濫用を防ぐための新規な持続放出製薬化合物
AU2022200089B2 (en) Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors
JP4732438B2 (ja) 上昇した血中尿素濃度を低減させるオリゴペプチド
US6337319B1 (en) μ-Selective opioid peptides
JP6170019B2 (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
JP2009533459A (ja) 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
EP2007762A2 (fr) Composes oxycodone mono et di-substitues et compositions correspondantes
AU2006350707A1 (en) Transdermal delivery systems of peptides and related compounds
US8080519B2 (en) Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US6908900B2 (en) Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
EP2896402A1 (fr) Molécules de neurotensine activés et leurs utilisations
CA2434831C (fr) Drogues a base de polypeptide
EP1351976A2 (fr) Analogues de gpe
AU2002228260A1 (en) Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US20080139670A1 (en) Drug Delivery System
KR19990044553A (ko) 펩티드 유도체
WO2007012838A2 (fr) Systeme d'administration de medicament
AU2016213759B2 (en) Transdermal delivery systems of peptides and related compounds
AU2014203176B2 (en) Transdermal delivery systems of peptides and related compounds
WO2009127140A1 (fr) Peptide 7p et son dérivé, ainsi que leur utilisation
CA2428971A1 (fr) Conjugues d'un agent therapeutique et d'un porteur peptidique
JPH10330399A (ja) 神経伝達ポリペプチド

Legal Events

Date Code Title Description
EEER Examination request